Chinese Journal of Dermatology ›› 2020, Vol. 53 ›› Issue (5): 390-394.doi: 10.35541/cjd.20190430
• Reviews • Previous Articles Next Articles
Zhu Guannan, Wang Gang
Received:2019-03-26
Revised:2019-09-21
Online:2020-05-15
Published:2020-04-30
Contact:
Wang Gang
E-mail:xjwgang@fmmu.edu.cn
Supported by:Zhu Guannan, Wang Gang. Role of interleukin-17A in the occurrence and treatment of psoriasis[J]. Chinese Journal of Dermatology, 2020, 53(5): 390-394.doi:10.35541/cjd.20190430
| ［1］ | Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis［J］. J Am Acad Dermatol, 2014,71（1）:141⁃150. doi: 10.1016/j.jaad.2013.12.036. |
| ［2］ | 马蕾, 薛海波, 高梅兰, 等. Notch1信号对银屑病患者外周血Th17细胞分化和功能的影响［J］. 中华皮肤科杂志, 2018,51（3）:189⁃193. doi: 10.3760/cma.j.issn.0412⁃4030.2018.03.006. |
| ［3］ | Takahashi H, Tsuji H, Hashimoto Y, et al. Serum cytokines and growth factor levels in Japanese patients with psoriasis［J］. Clin Exp Dermatol, 2010,35（6）:645⁃649. doi: 10.1111/j.1365⁃2230. 2009.03704.x. |
| ［4］ | Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis［J］. J Invest Dermatol, 2010,130（5）:1373⁃1383. doi: 10.1038/jid.2009.399. |
| ［5］ | Zhang L, Yang XQ, Cheng J, et al. Increased Th17 cells are accompanied by FoxP3（+） Treg cell accumulation and correlated with psoriasis disease severity［J］. Clin Immunol, 2010,135（1）:108⁃117. doi: 10.1016/j.clim.2009.11.008. |
| ［6］ | Brembilla NC, Senra L, Boehncke WH. The IL⁃17 family of cytokines in psoriasis: IL⁃17A and beyond［J］. Front Immunol, 2018,9:1682. doi: 10.3389/fimmu.2018.01682. |
| ［7］ | Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti⁃IL⁃17A biologic for the treatment of psoriasis［J］. Ther Adv Chronic Dis, 2018,9（1）:5⁃21. doi: 10.1177/2040622317738910. |
| ［8］ | Maione F. Commentary: IL⁃17 in chronic inflammation: from discovery to targeting［J］. Front Pharmacol, 2016,7:250. doi: 10. 3389/fphar.2016.00250. |
| ［9］ | Isailovic N, Daigo K, Mantovani A, et al. Interleukin⁃17 and innate immunity in infections and chronic inflammation［J］. J Autoimmun, 2015,60:1⁃11. doi: 10.1016/j.jaut.2015.04.006. |
| ［10］ | Teunissen M, Yeremenko NG, Baeten D, et al. The IL⁃17A⁃producing CD8+ T⁃cell population in psoriatic lesional skin comprises mucosa⁃associated invariant T cells and conventional T cells［J］. J Invest Dermatol, 2014,134（12）:2898⁃2907. doi: 10.1038/jid.2014.261. |
| ［11］ | 张洋洋, 李冰, 王刚. 银屑病皮损CD8αα+ T细胞表型鉴定［J］. 中华皮肤科杂志, 2018,51（10）:729⁃732. doi: 10.3760/cma.j.issn.0412⁃4030.2018.10.005. |
| ［12］ | Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL⁃17 through extracellular trap formation in psoriasis［J］. J Immunol, 2011,187（1）:490⁃500. doi: 10.4049/jimmunol. 1100123. |
| ［13］ | Kuwabara T, Ishikawa F, Kondo M, et al. The Role of IL⁃17 and related cytokines in inflammatory autoimmune diseases［J］. Mediators Inflamm, 2017,2017:3908061. doi: 10.1155/2017/390 8061. |
| ［14］ | Moos S, Mohebiany AN, Waisman A, et al. Imiquimod⁃induced psoriasis in mice depends on the IL⁃17 signaling of keratinocytes［J］. J Invest Dermatol, 2019,139（5）:1110⁃1117. doi: 10.1016/j.jid.2019.01.006. |
| ［15］ | Wu L, Chen X, Zhao J, et al. A novel IL⁃17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4⁃ERK5 axis［J］. J Exp Med, 2015,212（10）:1571⁃1587. doi: 10.1084/jem.20150204. |
| ［16］ | Gutowska⁃Owsiak D, Schaupp AL, Salimi M, et al. IL⁃17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion［J］. Exp Dermatol, 2012,21（2）:104⁃110. doi: 10.1111/j.1600⁃0625.2011.01412.x. |
| ［17］ | Nograles KE, Zaba LC, Guttman⁃Yassky E, et al. Th17 cytokines interleukin （IL）⁃17 and IL⁃22 modulate distinct inflammatory and keratinocyte⁃response pathways［J］. Br J Dermatol, 2008,159（5）:1092⁃1102. doi: 10.1111/j.1365⁃2133.2008.08769.x. |
| ［18］ | Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis［J］. J Invest Dermatol, 2009,129（9）:2175⁃2183. doi: 10.1038/jid.2009.65. |
| ［19］ | Schön MP, Erpenbeck L. The Interleukin⁃23/interleukin⁃17 axis links adaptive and innate immunity in psoriasis［J］. Front Immunol, 2018,9:1323. doi: 10.3389/fimmu.2018.01323. |
| ［20］ | Croxford AL, Karbach S, Kurschus FC, et al. IL⁃6 regulates neutrophil microabscess formation in IL⁃17A⁃driven psoriasiform lesions［J］. J Invest Dermatol, 2014,134（3）:728⁃735. doi: 10. 1038/jid.2013.404. |
| ［21］ | Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL⁃23/IL⁃17 signaling pathway and the treatment of psoriasis［J］. J Immunol, 2018,201（6）:1605⁃1613. doi: 10.4049/jimmunol.180 0013. |
| ［22］ | Sawyer L, Fotheringham I, Wright E, et al. The comparative efficacy of brodalumab in patients with moderate⁃to⁃severe psoriasis: a systematic literature review and network meta⁃analysis［J］. J Dermatolog Treat, 2018,29（6）:557⁃568. doi: 10.1080/09546634.2018.1427205. |
| ［23］ | Beck KM, Koo J. Brodalumab for the treatment of plaque psoriasis: up⁃to⁃date［J］. Expert Opin Biol Ther, 2019,19（4）:287⁃292. doi: 10.1080/14712598.2019.1579794. |
| ［24］ | Krueger JG, Wharton KA Jr, Schlitt T, et al. IL⁃17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis［J］. J Allergy Clin Immunol, 2019,144（3）:750⁃763. doi: 10.1016/j.jaci.2019.04.029. |
| ［25］ | McInnes IB, Nash P, Ritchlin C, et al. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta⁃analysis［J］. J Comp Eff Res, 2018,7（11）:1107⁃1123. doi: 10.2217/cer⁃2018⁃0075. |
| ［26］ | McInnes IB, Mease PJ, Schett G, et al. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study［J］. Arthritis Res Ther, 2018,20（1）:113. doi: 10.1186/s13075⁃018⁃1610⁃3. |
| ［27］ | Blauvelt A. Ixekizumab: a new anti⁃IL⁃17A monoclonal antibody therapy for moderate⁃to severe plaque psoriasis［J］. Expert Opin Biol Ther, 2016,16（2）:255⁃263. doi: 10.1517/14712598.2016. 1132695. |
| ［28］ | Ramaekers B, Wolff RF, Pouwels X, et al. Ixekizumab for treating moderate⁃to⁃severe plaque psoriasis: an evidence review group perspective of a NICE single technology appraisal［J］. Pharmacoeconomics, 2018,36（8）:917⁃927. doi: 10.1007/s40273⁃018⁃0629⁃2. |
| ［29］ | Kemény L, Berggren L, Dossenbach M, et al. Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER⁃2 and UNCOVER⁃3［J］. J Dermatolog Treat, 2019,30（1）:19⁃26. doi: 10.1080/09546634.2018.1473551. |
| ［30］ | Loos AM, Liu S, Segel C, et al. Comparative effectiveness of targeted immunomodulators for the treatment of moderate⁃to⁃severe plaque psoriasis: a systematic review and network meta⁃analysis［J］. J Am Acad Dermatol, 2018,79（1）:135⁃144.e7. doi: 10.1016/j.jaad.2018.02.027. |
| ［31］ | van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52⁃week results from a phase III study （SPIRIT⁃P1）［J］. J Rheumatol, 2018, 45（3）: 367⁃377. doi: 10.3899/jrheum.170429 |
| ［32］ | Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies［J］. J Allergy Clin Immunol, 2017,140（3）:645⁃653. doi: 10.1016/j.jaci.2017.07.004. |
| ［33］ | Mullard A. New plaque psoriasis approval carries suicide warning［J］. Nat Rev Drug Discov, 2017,16（3）:155. doi: 10.1038/nrd. 2017.44. |
| ［34］ | Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials［J］. J Am Acad Dermatol, 2018,78（1）:81⁃89.e5. doi: 10.1016/j.jaad.2017.08.024. |
| ［35］ | Lebwohl M. Reply to: "Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials"［J］. J Am Acad Dermatol, 2018,78（3）:e75. doi: 10.1016/j.jaad. 2017.11.028. |
| ［36］ | Rieder EA. In response to Lebwohl et al, "Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials"［J］. J Am Acad Dermatol, 2018,78（3）:e73. doi: 10.1016/j.jaad.2017.10.052. |
| [1] | Sun Jie, Wang Rui, Li Chengxin. Tumor necrosis factor-α inhibitor?induced psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 821-824. |
| [2] | Liu Jin, Shen Zhengyu. Epigenetic regulation in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 825-829. |
| [3] | Zheng Jiayuan, Yu Bingqian, Chen Xianxia, Luo Zhicheng. Characteristics of pruritus in adult patients with psoriasis vulgaris and its effect on quality of life [J]. Chinese Journal of Dermatology, 2022, 55(9): 790-794. |
| [4] | Xiao Chunying, Wang Gang. Roles of Langerhans cells in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 830-834. |
| [5] | Zhou Xue, Yu Zengyang, Chen Youdong, Guo Chunyuan, Yu Qian, Hu Yifan, Yao Lingling, Shi Yuling, . Tumor necrosis factor α-mediated low expression of fatty acid desaturase 2 in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 752-758. |
| [6] | Yao Lingling, Yu Zengyang, Guo Chunyuan, Zhou Jing, Cui Lian, Yu Qian, Yu Yingyuan, Zhou Xue, Cai Jiangluyi, Shi Yuling, . Changes in circadian gene cryptochrome 2 expression in mouse models of psoriasis and HaCaT cells and their underlying mechanisms [J]. Chinese Journal of Dermatology, 2022, 55(9): 759-766. |
| [7] | Yu Chen, Wang Gang. Small-molecule targeted agents: new choices for the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 747-751. |
| [8] | Wang Lingyan, Pan Jing, Miao Gang, Chang Xiaodan, Jin Qiuzi, Guo Ningning, Zhang Jiayu. Analysis of difficult-to-treat sites in patients with psoriasis who received biological therapy [J]. Chinese Journal of Dermatology, 2022, 55(7): 583-587. |
| [9] | Committee on Autoimmune Diseases, China Dermatologist Association. Cyclosporine in the treatment of immune-related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2022, 55(6): 471-479. |
| [10] | Shan Ying, Zuo Yagang. Correlation between autoimmune bullous diseases and psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(5): 452-455. |
| [11] | Wang Yue, Yan Yulin. Analysis of adverse drug reactions and reasons for drug discontinuation during acitretin therapy in 171 patients with psoriasis vulgaris [J]. Chinese Journal of Dermatology, 2022, 55(3): 242-245. |
| [12] | Li Yan, Li Ming, Xu Wei, Li Linfeng. Efficacy of fluticasone propionate cream alone or in combination with calcipotriol ointment in the treatment of mild to moderate plaque psoriasis: a randomized self-controlled study [J]. Chinese Journal of Dermatology, 2022, 55(3): 260-263. |
| [13] | Wang Zhaoyang, Chen Anwei, Xiang Xin, Luo Xiaoyan, Xu Zigang, Wang Hua, Ma Lin. An investigation into the current situation of pediatric psoriasis based on the information systems from two children′s hospitals [J]. Chinese Journal of Dermatology, 2022, 55(3): 246-250. |
| [14] | Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022） [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195. |
| [15] | Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275. |
|
